The Exchange has sought clarification from Camlin Fine Sciences Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked Camlin Fine Sciences to clarify discrepancies found in the financial results it filed in XBRL format for the quarter ended 31 March 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. This relates to the company's quarterly financial submissions. The company's response is still awaited. XBRL is the standard digital format companies use to file financial data with stock exchanges. Discrepancies could mean mismatches between the data filed and the audited results.
This appears to be a routine regulatory clarification request rather than a punitive action. Investors should watch for the company's response, as unresolved discrepancies could lead to further regulatory queries or affect the credibility of the reported numbers.